semaglutide bone density loss Does Reduce Muscle Mass GLP-1 Medications, Weight Loss &

Acknowledgments The authors gratefully acknowledge the critical reviews and insights of Sarah Armstrong MD, Nancie MacIver MD PhD, and Lisa Rasbach PhD CPNP

Expected research outcomes and timelines Tirzepatide research has generated extensive data on expected outcomes across multiple domains

Retatrutide is a triple hormone receptor agonist (GLP-1, GIP, glucagon) under Phase 3 investigation

Occurrence of gastrointestinal adverse events upon GLP-1 receptor agonist initiation with concomitant metformin use: A post hoc analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes that was subsequently found to produce substantial weight loss